Business Description
HUTCHMED (China) Ltd
ISIN : KYG4672N1016
Total Employee Number:
1,796Compare
Compare
Traded in other countries / regions
HCM.UK00013.Hong KongHCM.USAH7T2.Germany IPO Date
2006-05-19Description
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 13.97 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | 0.19 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.08 | |||||
Beneish M-Score | -1.24 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.3 | |||||
3-Year FCF Growth Rate | 36.4 | |||||
3-Year Book Growth Rate | 22 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 14.36 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.16 | |||||
9-Day RSI | 45.04 | |||||
14-Day RSI | 45.69 | |||||
3-1 Month Momentum % | -23.64 | |||||
6-1 Month Momentum % | -22.58 | |||||
12-1 Month Momentum % | -27.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.96 | |||||
Quick Ratio | 4.83 | |||||
Cash Ratio | 4.33 | |||||
Days Inventory | 51.62 | |||||
Days Sales Outstanding | 97.47 | |||||
Days Payable | 48.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.6 | |||||
Shareholder Yield % | -0.31 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 38.67 | |||||
Operating Margin % | -6.54 | |||||
Net Margin % | 82.75 | |||||
EBITDA Margin % | 94.5 | |||||
FCF Margin % | -16.07 | |||||
OCF Margin % | -11.69 | |||||
ROE % | 41.55 | |||||
ROA % | 27.86 | |||||
ROIC % | -7.45 | |||||
3-Year ROIIC % | -680.38 | |||||
ROC (Joel Greenblatt) % | 512.42 | |||||
ROCE % | 39.58 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 4.31 | |||||
Forward PE Ratio | 43.59 | |||||
Price-to-Owner-Earnings | 4.98 | |||||
PS Ratio | 3.53 | |||||
PB Ratio | 1.53 | |||||
Price-to-Tangible-Book | 1.54 | |||||
EV-to-EBIT | 1.25 | |||||
EV-to-Forward-EBIT | 62.72 | |||||
EV-to-EBITDA | 1.21 | |||||
EV-to-Forward-EBITDA | 187.81 | |||||
EV-to-Revenue | 1.15 | |||||
EV-to-Forward-Revenue | 1.03 | |||||
EV-to-FCF | -7.14 | |||||
Price-to-GF-Value | 0.78 | |||||
Price-to-Median-PS-Value | 0.34 | |||||
| Price-to-Net-Current-Asset-Value | 1.81 | |||||
| Price-to-Net-Cash | 2.23 | |||||
Earnings Yield (Greenblatt) % | 80 | |||||
FCF Yield % | -4.61 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
HUTCHMED (China) Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 406.962 | ||
| EPS (TTM) (£) | 0.383 | ||
| Beta | 0.3469 | ||
| 3-Year Sharpe Ratio | -0.02 | ||
| 3-Year Sortino Ratio | -0.02 | ||
| Volatility % | 34.37 | ||
| 14-Day RSI | 45.69 | ||
| 14-Day ATR (£) | 0.09529 | ||
| 20-Day SMA (£) | 1.638875 | ||
| 12-1 Month Momentum % | -27.27 | ||
| 52-Week Range (£) | 1.5048 - 2.92 | ||
| Shares Outstanding (Mil) | 859.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
HUTCHMED (China) Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
HUTCHMED (China) Ltd Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-07-30 08:00 | In 18 days | ||
| Second quarter earnings results for 2026 | 2026-07-30 | In 17 days | ||
| General meeting for 2026 | 2026-05-12 16:00 | 1.91 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 13:00 | 2.06 (+1.98%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 11:00 | 2.06 (+1.98%) | ||
| Annual report for 2025 | 2026-03-05 | 2.06 (+1.98%) | ||
| American Society of Hematology (\"ASH\") Annual Meeting | 2025-12-06 | 2.13 (+0.95%) | ||
| Guidance call for 2025 | 2025-12-05 | 2.14 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2025-11-17 15:30 | 2.28 (-0.44%) | ||
| Deutsche Bank Depositary Receipts Virtual Investor Conference | 2025-11-04 | 2.34 (+6.36%) |
Show
Entries
HUTCHMED (China) Ltd Frequently Asked Questions
What is HUTCHMED (China) Ltd(LSE:HCM)'s stock price today?
The current price of LSE:HCM is £1.65. The 52 week high of LSE:HCM is £2.92 and 52 week low is £1.50.
When is next earnings date of HUTCHMED (China) Ltd(LSE:HCM)?
The next earnings date of HUTCHMED (China) Ltd(LSE:HCM) is 2026-07-30.
Does HUTCHMED (China) Ltd(LSE:HCM) pay dividends? If so, how much?
HUTCHMED (China) Ltd(LSE:HCM) does not pay dividend.
Press Release
Articles on HUTCHMED (China) Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers